Alantra advised Cinfa on the acquisition of Sakura in Italy
Alantra advised Spanish pharmaceutical and health group Cinfa on the acquisition of Sakura, a family owned Italian Consumer Health company with a range of very innovative products, marketed exclusively via medical detailing.
Cinfa is a Spanish pharmaceutical laboratory with the largest household penetration in Spain. Its 900 employees develop a comprehensive vademecum including five different product ranges: generic drugs, OTC products, orthopaedics, dermo-cosmetics and nutritional solutions. The company is present in 50 countries around the world.
Founded in 2004, Sakura is an Italian pharmaceutical group specialized in the research and development of innovative natural products for the health, the wellbeing and the quality life of the person. In 2011 Sakura started its international expansion and at present they are established in 24 countries.
This deal marks Alantra’s second transaction with Cinfa in the last six months, following the acquisition of Natural Santé, a French group specialized in developing natural food supplements in pharmacies. Cinfa mandated Alantra to accompany it in its international growth plan and to decrease its dependency of the generic business. With this transaction the company not only reinforces its presence in the Italian market but gains a strong position in the growing food supplement market and Consumer Health sector.
Jan 2020Buy-side advisoryJan 2020SECTOR HealthcareService M&A
Dec 2019Debt financingDec 2019SECTOR HealthcareService Debt Advisory
Oct 2019Buy-side advisoryValue $10.4 millionOct 2019SECTOR HealthcareService M&AValue $10.4 million
Sep 2019Buy-side advisorySep 2019SECTOR HealthcareService Debt Advisory